SuperworthViridian Therapeutics shares outstanding VRDN
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2025
- 81.6M
- On a year earlier
- +27.8%
- more shares
Viridian Therapeutics had 81.6M diluted shares outstanding on average in Q2 FY25, the quarter to Jun 30, 2025.
That is 27.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2023 | 49.8M | +23% |
| FY2022 | 40.5M | +83% |
| FY2021 | 22.1M | +462% |
| FY2020 | 3.9M | +82% |
| FY2019 | 2.2M | +5% |
| FY2018 | 2.1M | +38% |
| FY2017 | 1.5M | +3326% |
| FY2016 | 43.4K | −8% |
| FY2015 | 47.3K | +163% |
| FY2014 | 18K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY25 | 81.6M | +28% | |
| Q1 FY25 | 81.3M | +33% | |
| Q3 FY24 | 66.4M | +52% | |
| Q2 FY24 | 63.9M | +48% | |
| Q1 FY24 | 61.1M | +45% | |
| Q4 FY23 | 49.8M | +23% | |
| Q3 FY23 | 43.7M | +29% | |
| Q2 FY23 | 43.3M | +56% | |
| Q1 FY23 | 42.2M | +62% | |
| Q4 FY22 | 40.5M | +83% | |
| Q3 FY22 | 33.7M | +202% | |
| Q2 FY22 | 27.8M | +242% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Viridian Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.